Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)
3.3.2023 16:00:00 EET | Business Wire | Press release
Viz.ai, a leader in AI-powered disease detection and care coordination, today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY), a global biopharmaceutical company, to deploy an artificial intelligence (AI) algorithm and provider workflow software (VizTM HCM) intended to identify and triage patients who may require further evaluation for the detection of hypertrophic cardiomyopathy. Viz.ai has submitted a de novo request to the U.S. Food and Drug Administration (FDA) for the algorithm as a Software-as-a-Medical-Device (SaMD), and the filing has been accepted by the agency for review.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230303005086/en/
Viz.ai Announces Agreement with Bristol Myers Squibb on Hypertrophic Cardiomyopathy (Graphic: Business Wire)
“HCM is the most common inherited heart disease with an estimated prevalence between 1 in 200 and 1 in 500, and one of the leading causes of sudden cardiac death in people under age 35,” said David Huneycutt, M.D., F.A.C.C., a cardiologist at HCA Healthcare’s TriStar Centennial Medical Center in Nashville, Tenn. and an enterprise-wide cardiovascular physician director. “Since a high percentage of patients remain undiagnosed, it is critical that we find solutions to identify patients with suspected HCM sooner.”
HCM is defined by thickened heart muscle, which can make it harder for the heart to pump blood. It is associated with increased risks of atrial fibrillation, mitral valve disease, and heart failure. HCM is estimated to impact an estimated 750,000 people in the United States and 20 million worldwide.1
“At BMS, we believe that the use of AI to detect key, subtle characteristics in bio signals to aid physicians in the screening, diagnosis, treatment and monitoring of diseases will have a critical and positive impact on patients’ lives,” said Suhas Krishna, Vice President, Head of Digital Health Product Management, Bristol Myers Squibb. “We are excited to continue building momentum in our support of Viz.ai’s research and development program. The speed and quality in which this novel AI algorithm & workflow sequencing product was designed, verified, validated, and submitted by Viz.ai for agency review is testament to the ability to drive rapid and meaningful innovation in healthcare.”
Viz HCM is intended to automatically review routine electrocardiograms (ECGs) from across a health system, identify suspected cases of HCM, and notify the appropriate cardiologist. The physician can then review the ECG in a timely manner and take the appropriate clinical action, including recommending follow-up diagnostic testing in parallel to the standard of care. Viz HCM will be integrated into the Viz.ai Cardio Suite for U.S. hospitals, which is expected to advance cardiac care coordination through a mobile-based electrocardiogram viewer, built with timely AI-powered alerts and communication tools. The Viz.ai Intelligent Care Coordination Platform, which includes Viz.ai Cardio Suite, is adopted by nearly 1,300 hospitals in the U.S. Viz.ai has placed Viz HCM at several hospitals, including select HCA Healthcare facilities, under research agreements to further evaluate the product in clinical practice. The company plans to launch Viz HCM broadly upon FDA clearance.
“Hypertrophic cardiomyopathy can be a devastating disease. The agreement with Bristol Myers Squibb gives us the opportunity to enable underdiagnosed and underserved HCM patients to get the care they need from appropriate providers at the right time,” said Dr. Chris Mansi, CEO at Viz.ai. “Incorporating the new HCM module into the Viz Cardio Suite is expected to enhance detection, expedite care, and empower clinicians and patients.”
For more information on Viz HCM for research, please visit https://www.viz.ai/research/hcm.
*Viz HCM not available for sale. Investigational use only
1 Maron BJ. N Engl J Med. 2018; 379:655-68.
About Viz.ai, Inc.
Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase access to life-saving treatments, covering more than 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients, informs critical decisions at the point of care, and helps improve outcomes. Backed by real-world clinical data, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230303005086/en/
Contact information
Ariane Lovell
ariane.lovell@finnpartners.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 22:50:00 EET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 16:38:00 EET | Press release
Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net profit was at €250.9 million. In 2024, the corresponding value was €211.1 million. Following the results achieved in 2025, the Reply Board of Directors decided to propose to the next Shareholders’ Meeting a dividend distribution of €1.35 per share, which will be payable on 20 May 2026, with dividend date set on 18 May 2026 (record
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 15:51:00 EET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 15:30:00 EET | Press release
Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and collaborations with leading pharmaceutical companies, including MSD since 2023 for MSIntuit, Waiv is establishing itself as a leader in translational medical AI. Waiv leverages a decade of Owkin's foundational medical AI research, including access to an extensive patient data net
RQM+ Launches SMART Solutions Life Cycle Partnership Model12.3.2026 15:30:00 EET | Press release
RQM+, a leading MedTech CRO offering regulatory consulting, clinical trial, laboratory, and reimbursement services, today announced the launch of SMART Solutions, a life cycle partnership model designed to help medical device and diagnostics companies manage growing regulatory and development complexity. SMART Solutions introduces a strategy-led operating framework that unifies regulatory, quality, clinical, reimbursement, and laboratory expertise to support MedTech companies across the entire product life cycle to help reduce risk from early development through post-market. “MedTech companies are navigating unprecedented complexity as regulatory expectations evolve, product innovation accelerates, and post-market expectations are expanding,” said John Potthoff, Ph.D., chief executive officer of RQM+. “SMART Solutions moves beyond traditional consulting by providing an integrated life cycle partnership that helps sponsors gain earlier clarity, reduce risk, and execute complex programs
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom